Ozempic Gastroparesis Attorney: Understanding the Statute of Limitations in Pennsylvania

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Patient-Centered Accountability

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy context emphasized broad awareness of wellness, disease mechanisms, and therapeutic interventions, often focusing on lifestyle factors and common pharmacological agents. Within this framework, medications such as Ozempic emerged as part of a larger conversation about metabolic health, specifically in relation to glucose regulation and weight management. As public discourse evolved, the scope of health information expanded to include not only intended therapeutic benefits but also potential adverse effects associated with long-term medication use. This shift naturally led to increased scrutiny of drug safety profiles and the emergence of specialized legal considerations. In the occupational and consumer exposure context, individuals who have used Ozempic may now face concerns regarding delayed gastric emptying, a condition known as gastroparesis. For those affected in Pennsylvania, understanding the applicable statute of limitations becomes critical when considering legal recourse. The transition from general health education to this specific exposure concern reflects a broader movement toward patient-centered accountability, where historical knowledge of drug mechanisms informs contemporary risk assessment and legal strategy.

Ozempic and Gastroparesis: The Medical Evidence

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known adverse effects, gastrointestinal reactions are prominent. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Gastroparesis is a clinical syndrome characterized by delayed gastric emptying in the absence of mechanical obstruction. Its presentation includes early satiety, postprandial fullness, nausea, vomiting, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests. The mechanistic pathways linking GLP-1 receptor agonists like Ozempic to gastroparesis involve the drug's pharmacological action: GLP-1 receptor agonists slow gastric emptying as part of their glucose-lowering effect. This delay can become clinically significant, leading to symptoms consistent with gastroparesis.

Label Warnings and Risk Context

The label for Ozempic acknowledges this risk indirectly through warnings about pulmonary aspiration during elective surgeries or procedures requiring general anesthesia or deep sedation. The label states: 'There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This indicates that retained gastric contents, a hallmark of gastroparesis, can occur in patients taking Ozempic. The adequacy of warnings regarding Ozempic and gastroparesis is a key risk anchor. The label does not explicitly list gastroparesis as a contraindication or warning. Instead, it focuses on gastrointestinal adverse reactions and aspiration risk. The label advises: 'Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking RYBELSUS or OZEMPIC tablets' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). However, it does not provide specific guidance on monitoring for gastroparesis symptoms or discontinuing the drug in patients who develop such symptoms. This gap may be relevant for patients who experience persistent nausea, vomiting, or abdominal pain while on Ozempic, as these could be early signs of gastroparesis.

Statute of Limitations for Ozempic Claims in Pennsylvania

For affected patients in Pennsylvania, attorney-related considerations include the statute of limitations for product liability claims. In Pennsylvania, the statute of limitations for personal injury claims, including those related to defective drugs, is generally two years from the date the injury was discovered or should have been discovered. This timeline is critical because gastroparesis symptoms may develop gradually, and patients might not immediately connect them to Ozempic use. The timeline between exposure to Ozempic and documented harm can vary. Gastrointestinal adverse reactions often occur during dose escalation, but gastroparesis may develop after months or years of use. The label notes that gastrointestinal adverse reactions occurred more frequently during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but the risk of retained gastric contents persists. Observational evidence suggests that extended GLP-1 RA withholding, 24-hour clear liquid diets, and pre-procedural gastric point-of-care ultrasound may be associated with reduced retained gastric contents in selected patient populations, but the evidence base remains limited, and a modest aspiration risk cannot be excluded (https://pubmed.ncbi.nlm.nih.gov/42245865/). This underscores the uncertainty around the duration of risk. Patients considering legal action should document the timing of Ozempic initiation, dose changes, onset of gastrointestinal symptoms, and any medical diagnoses of gastroparesis. They should also preserve all prescription records, medical records, and communications with healthcare providers. The statute of limitations clock may start when a patient is diagnosed with gastroparesis or when they reasonably should have connected their symptoms to Ozempic. Given the complexity of these cases, consulting with an attorney experienced in pharmaceutical litigation is advisable.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for an Ozempic gastroparesis claim in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury claims, including product liability claims related to Ozempic, is generally two years from the date the injury was discovered or should have been discovered. This means that if you developed gastroparesis after taking Ozempic, you have two years from the date you knew or reasonably should have known that your injury was linked to the medication to file a lawsuit.

Does the Ozempic label warn about gastroparesis?

The Ozempic label does not explicitly list gastroparesis as a contraindication or warning. However, it does warn about gastrointestinal adverse reactions and the risk of pulmonary aspiration due to retained gastric contents during surgeries. The label advises patients to inform healthcare providers before any planned surgeries if they are taking Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This gap in explicit warning may be relevant for patients who develop gastroparesis symptoms.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.